Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Tirzepatide crosses your target, drops, or sets a new tracked low—without daily noise.

Public product evidence 478 certificate records for Tirzepatide products, from 58 vendors 286 reference a report on the testing laboratory's own system · 201 have a laboratory lookup that answered when last checked · 441 match a vendor product page at the same address

Status

FDA Approved

This peptide maps to at least one regulated medical product or label context in the United States.

Research area

Metabolic / incretin research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Aliases

Mounjaro, Zepbound

Signal depth

High

FDA label signal · 318 trials · 2608 PubMed results

Established

Research evidence

Tirzepatide is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Tirzepatide has 72 name-matched clinical trials (3 international) (highest phase: Phase 4) and 2608 PubMed-indexed publications and holds an FDA drug label. 20 trials have posted results.

🌍 3 international trials FAERS (approved drug): 3,153

Human data

Approved drug

Trial quality

Large RCT

Outcomes

Clinical outcomes

Replication

Meta-analysis

Literature

Top-tier journals

PHASE4 · Randomized A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) PHASE4 · Randomized AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) PHASE4 A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity ISRCTN Weight reduction in asthma programme with tirzepatide ISRCTN · Phase 2 A phase 2, safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy study of a subcutaneous injection of BC-006 and tirzepatide in adults with obesity New England Journal of Medicine · 3,697 citations Tirzepatide Once Weekly for the Treatment of Obesity

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-03 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What tirzepatide is

Tirzepatide is a dual agonist that targets both GIP and GLP-1 pathways. It is marketed in FDA-approved products including Mounjaro and Zepbound, with the indication depending on the specific label.

Why it stands out

Tirzepatide matters because it moved beyond the single-pathway GLP-1 story and helped establish the market for dual- and triple-agonist obesity therapeutics.

Regulatory context

FDA announced the approval of Zepbound for chronic weight management on November 8, 2023:

FDA approval letter for Zepbound (NDA 217806)

FDA has also published safety and enforcement material addressing unapproved versions of tirzepatide sold outside approved channels:

FDA concerns with unapproved GLP-1 drugs

Why that matters for researchers

Tirzepatide is a good example of how fast the public conversation can outrun the regulatory one. The ingredient may be familiar, but product category still matters:

FDA-approved branded product
compounded product
research-market listing

Those carry different expectations for quality control, labeling, and oversight.

Where tirzepatide fits in the landscape

If semaglutide helped normalize GLP-1-based weight management, tirzepatide helped raise the performance ceiling and opened the door for the newer triple-agonist pipeline that includes compounds like retatrutide.